Olivier Harismendy
Overview
Explore the profile of Olivier Harismendy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
3528
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jameson N, Kim D, Lee C, Skrable B, Shea A, Guo X, et al.
Cancer Res Commun
. 2025 Jan;
5(2):240-252.
PMID: 39807828
Resistance to KRASG12C inhibitors is a growing clinical concern. The synergistic interaction observed between azenosertib and multiple KRASG12C inhibitors could result in deeper and more durable responses.
2.
Kim D, Chung H, Liu W, Jeong K, Ozmen T, Ozmen F, et al.
NPJ Precis Oncol
. 2025 Jan;
9(1):3.
PMID: 39755818
Upregulation of Cyclin E1 and subsequent activation of CDK2 accelerates cell cycle progression from G1 to S phase and is a common oncogenic driver in gynecological malignancies. WEE1 kinase counteracts...
3.
Allevato M, Trinh S, Koshizuka K, Nachmanson D, Nguyen T, Yokoyama Y, et al.
Cancer Lett
. 2024 Jul;
598:217089.
PMID: 38964731
Glutamine is a conditionally essential amino acid for the growth and survival of rapidly proliferating cancer cells. Many cancers are addicted to glutamine, and as a result, targeting glutamine metabolism...
4.
Borowsky A, Glencer A, Ramalingam K, Schindler N, Mori H, Ghule P, et al.
Res Sq
. 2024 May;
PMID: 38766192
Ductal carcinoma (DCIS) constitutes an array of morphologically recognized intraductal neoplasms in the mammary ductal tree defined by an increased risk for subsequent invasive carcinomas at or near the site...
5.
OKeefe T, Yau C, Iaconetti E, Jeong E, Brabham C, Kim P, et al.
Res Sq
. 2024 Jan;
PMID: 38260526
Ductal carcinoma in situ (DCIS) incidence has risen rapidly with the introduction of screening mammography, yet it is unclear who benefits from both the amount and type of adjuvant treatment...
6.
Semaan A, Bernard V, Wong J, Makino Y, Swartzlander D, Rajapakshe K, et al.
Cancer Res Commun
. 2023 Sep;
3(10):2062-2073.
PMID: 37721516
Significance: Integrated molecular analysis of genomic and transcriptomic alterations in the multistep progression of IPMNs, which are bona fide precursors of pancreatic cancer, identifies features associated with progression of low-risk...
7.
Pagadala M, Sears T, Wu V, Perez-Guijarro E, Kim H, Castro A, et al.
Nat Commun
. 2023 May;
14(1):2744.
PMID: 37173324
With the continued promise of immunotherapy for treating cancer, understanding how host genetics contributes to the tumor immune microenvironment (TIME) is essential to tailoring cancer screening and treatment strategies. Here,...
8.
OKeefe T, Harismendy O, Wallace A
Chin Clin Oncol
. 2023 Mar;
12(1):3.
PMID: 36922359
Background: Rates of mastectomy for patients with localized breast cancer remain high despite decades of evidence that breast conservation therapy is equally effective. The impact of progesterone receptor (PR) status...
9.
Arang N, Lubrano S, Rigiracciolo D, Nachmanson D, Lippman S, Mali P, et al.
J Biol Chem
. 2023 Jan;
299(2):102866.
PMID: 36596361
G proteins and G protein-coupled receptors activate a diverse array of signal transduction pathways that promote cell growth and survival. Indeed, hot spot-activating mutations in GNAQ/GNA11, encoding Gαq proteins, are...
10.
Nachmanson D, Pagadala M, Steward J, Cheung C, Keeler Bruce L, Lee N, et al.
J Transl Med
. 2022 Dec;
20(1):623.
PMID: 36575447
Purpose: The contribution of common genetic variants to pre-cancer progression is understudied due to long follow-up time, rarity of poor outcomes and lack of available germline DNA collection. Alternatively, DNA...